Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 10—October 2005

Dispatch

Drug-resistant Escherichia coli, Rural Idaho

Elizabeth L. Hannah*Comments to Author , Frederick J. Angulo†, James R. Johnson‡§, Bassam Haddadin*, Jacquelyn Williamson*, and Matthew H. Samore*¶
Author affiliations: *University of Utah School of Medicine, Salt Lake City, Utah, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Veterans Administration Medical Center, Minneapolis, Minnesota, USA; §University of Minnesota, Minneapolis, Minnesota, USA; ¶Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah, USA

Main Article

Table 3

Healthcare/antimicrobial use in 517 study participants collected from questionnaires and pharmacy data*

Characteristic No. (%)
Ambulatory visit in past 6 mo 266 (52)
Diabetic 13 (3)
Antimicrobial use in past month 37 (7)
No. outpatient visits (past 6 mo)
0 251 (49)
1 125 (49)
2 59 (23)
3 29 (11)
4 14 (5)
>5 32 (12)
No. hospitalizations (past 6 mo)
0 483 (93)
1 31 (6)
2 2 (0)
3 1 (0)
No. courses of antimicrobial agents in the past year
0 333 (64)
1 91 (18)
2 39 (8)
3 19 (4)
4 16 (3)
>5 19 (4)
Antimicrobial classes, no. with >1 course
TMP/SMZ
Past month 2 (0.4)
Past year 10 (2)
Fluoroquinolones
Past month 7 (1)
Past year 17 (3)
Cephalosporins
Past month 4 (1)
Past year 37 (7)
Penicillin
Past month 18 (4)
Past year 107 (21)
Macrolide
Past month 3 (1)
Past year 24 (5)

*TMP/SMZ, trimethoprim/sulfamethoxazole.

Main Article

TOP